NO20003848D0 - FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien - Google Patents

FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien

Info

Publication number: NO20003848D0
Authority: NO; Norway
Prior art keywords: lymphotoxin; follicular lymphoma; pathway inhibitors; treating follicular; treating
Prior art date: 1998-01-30

Application number

NO20003848A

Other languages

English (en)

Other versions

NO20003848L (no

NO328116B1 (no

Inventor

Jeffrey Browning

Jeanette Thorbecke

Vincent Tsiagbe

Original Assignee

Biogen Inc

Univ New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-30

Filing date

2000-07-27

Publication date

2000-07-27

2000-07-27 Application filed by Biogen Inc, Univ New York filed Critical Biogen Inc

2000-07-27 Publication of NO20003848D0 publication Critical patent/NO20003848D0/no

2000-10-02 Publication of NO20003848L publication Critical patent/NO20003848L/no

2009-12-14 Publication of NO328116B1 publication Critical patent/NO328116B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C07K16/242—Lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20003848A 1998-01-30 2000-07-27 Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. NO328116B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7311298P	1998-01-30	1998-01-30
US7341098P	1998-02-02	1998-02-02
PCT/US1999/001928 WO1999038525A1 (en)	1998-01-30	1999-01-29	Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (3)

Publication Number	Publication Date
NO20003848D0 true NO20003848D0 (no)	2000-07-27
NO20003848L NO20003848L (no)	2000-10-02
NO328116B1 NO328116B1 (no)	2009-12-14

Family

ID=26754147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20003848A NO328116B1 (no)	1998-01-30	2000-07-27	Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom.

Country Status (24)

Country	Link
EP (1)	EP1051187B9 (no)
JP (2)	JP4713733B2 (no)
KR (1)	KR100622960B1 (no)
CN (1)	CN1287853C (no)
AT (1)	ATE253930T1 (no)
AU (1)	AU752710B2 (no)
BR (1)	BR9908214A (no)
CA (1)	CA2319698A1 (no)
CZ (1)	CZ301026B6 (no)
DE (1)	DE69912743T2 (no)
DK (1)	DK1051187T3 (no)
EA (1)	EA003862B1 (no)
EE (1)	EE05235B1 (no)
ES (1)	ES2211035T3 (no)
HU (1)	HU226044B1 (no)
IL (2)	IL137489A0 (no)
IS (1)	IS2254B (no)
NO (1)	NO328116B1 (no)
NZ (1)	NZ506529A (no)
PL (1)	PL203279B1 (no)
PT (1)	PT1051187E (no)
SK (1)	SK285725B6 (no)
TR (2)	TR200002203T2 (no)
WO (1)	WO1999038525A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5406000A (en) *	1999-06-28	2001-01-31	Basf Aktiengesellschaft	Method for preventing tumoral growth
WO2001058953A2 (en)	2000-02-11	2001-08-16	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
YU28503A (sh)	2000-10-13	2006-05-25	Biogen Inc.	Humanizovana anti-lt-beta-r antitela
BR0308250A (pt)	2002-03-04	2005-01-11	Aton Pharma Inc	Métodos de indução de diferenciação terminal
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
WO2004002431A2 (en)	2002-07-01	2004-01-08	Biogen, Inc.	Humanized anti-lymphotoyin beta receptor antibodies
WO2004016317A1 (en) *	2002-08-14	2004-02-26	Erasmus University Medical Center Rotterdam	Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
US20060122132A1 (en) *	2002-08-14	2006-06-08	Touw Ivo P	Use of murine genomic regions identified to be involved in tumor developement for the development of anti-cancer drugs and diagnosis of cancer
CA2530388A1 (en)	2003-06-27	2005-01-06	Biogen Idec Ma Inc.	Modified binding molecules comprising connecting peptides
JP2007530588A (ja)	2004-03-23	2007-11-01	バイオジェン・アイデック・エムエイ・インコーポレイテッド	レセプターカップリング剤およびその治療用途
WO2006074399A2 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) *	2006-05-17	2014-11-26	上海复旦张江生物医药股份有限公司	淋巴毒素在制备增加化疗药物敏感性的药物中的应用
AU2007311052B2 (en)	2006-10-20	2014-01-16	Biogen Idec Ma Inc.	Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747023A (en) *	1994-07-01	1998-05-05	Genentech, Inc.	Cancer therapy using lymphotoxin
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) *	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Novel receptor protein and its use

1999
- 1999-01-29 TR TR2000/02203T patent/TR200002203T2/xx unknown
- 1999-01-29 ES ES99903480T patent/ES2211035T3/es not_active Expired - Lifetime
- 1999-01-29 AT AT99903480T patent/ATE253930T1/de active
- 1999-01-29 BR BR9908214-4A patent/BR9908214A/pt not_active IP Right Cessation
- 1999-01-29 EA EA200000798A patent/EA003862B1/ru not_active IP Right Cessation
- 1999-01-29 EE EEP200000446A patent/EE05235B1/xx not_active IP Right Cessation
- 1999-01-29 AU AU23488/99A patent/AU752710B2/en not_active Ceased
- 1999-01-29 DE DE69912743T patent/DE69912743T2/de not_active Expired - Lifetime
- 1999-01-29 IL IL13748999A patent/IL137489A0/xx unknown
- 1999-01-29 TR TR2001/01693T patent/TR200101693T2/xx unknown
- 1999-01-29 PL PL342063A patent/PL203279B1/pl unknown
- 1999-01-29 JP JP2000529257A patent/JP4713733B2/ja not_active Expired - Fee Related
- 1999-01-29 DK DK99903480T patent/DK1051187T3/da active
- 1999-01-29 CN CNB998024902A patent/CN1287853C/zh not_active Expired - Fee Related
- 1999-01-29 SK SK1130-2000A patent/SK285725B6/sk not_active IP Right Cessation
- 1999-01-29 CZ CZ20002751A patent/CZ301026B6/cs not_active IP Right Cessation
- 1999-01-29 KR KR1020007008353A patent/KR100622960B1/ko not_active Expired - Fee Related
- 1999-01-29 CA CA002319698A patent/CA2319698A1/en not_active Abandoned
- 1999-01-29 EP EP99903480A patent/EP1051187B9/en not_active Expired - Lifetime
- 1999-01-29 HU HU0102363A patent/HU226044B1/hu not_active IP Right Cessation
- 1999-01-29 NZ NZ506529A patent/NZ506529A/xx not_active IP Right Cessation
- 1999-01-29 PT PT99903480T patent/PT1051187E/pt unknown
- 1999-01-29 WO PCT/US1999/001928 patent/WO1999038525A1/en not_active Ceased
2000
- 2000-07-21 IS IS5570A patent/IS2254B/is unknown
- 2000-07-25 IL IL137489A patent/IL137489A/en not_active IP Right Cessation
- 2000-07-27 NO NO20003848A patent/NO328116B1/no not_active IP Right Cessation
2010
- 2010-06-22 JP JP2010142108A patent/JP2010235621A/ja active Pending

Also Published As

Publication number	Publication date
EE200000446A (et)	2001-08-15
AU2348899A (en)	1999-08-16
KR100622960B1 (ko)	2006-09-12
JP4713733B2 (ja)	2011-06-29
HUP0102363A3 (en)	2004-04-28
DE69912743D1 (de)	2003-12-18
CA2319698A1 (en)	1999-08-05
IL137489A0 (en)	2001-07-24
IL137489A (en)	2010-05-31
SK11302000A3 (sk)	2001-01-18
EP1051187B1 (en)	2003-11-12
TR200002203T2 (tr)	2000-12-21
HUP0102363A2 (hu)	2001-10-28
DK1051187T3 (da)	2004-03-08
CZ20002751A3 (cs)	2000-12-13
JP2010235621A (ja)	2010-10-21
TR200101693T2 (tr)	2002-06-21
EE05235B1 (et)	2009-12-15
HU226044B1 (en)	2008-03-28
NZ506529A (en)	2002-12-20
IS2254B (is)	2007-06-15
NO20003848L (no)	2000-10-02
BR9908214A (pt)	2000-11-28
EA200000798A1 (ru)	2001-02-26
EA003862B1 (ru)	2003-10-30
ES2211035T3 (es)	2004-07-01
CN1289252A (zh)	2001-03-28
EP1051187B9 (en)	2004-08-11
EP1051187A1 (en)	2000-11-15
KR20010040497A (ko)	2001-05-15
SK285725B6 (sk)	2007-07-06
CZ301026B6 (cs)	2009-10-14
JP2002501902A (ja)	2002-01-22
ATE253930T1 (de)	2003-11-15
HK1029944A1 (en)	2001-04-20
NO328116B1 (no)	2009-12-14
IS5570A (is)	2000-07-21
PL342063A1 (en)	2001-05-21
CN1287853C (zh)	2006-12-06
PL203279B1 (pl)	2009-09-30
PT1051187E (pt)	2004-03-31
DE69912743T2 (de)	2004-09-23
AU752710B2 (en)	2002-09-26
WO1999038525A1 (en)	1999-08-05

Publication	Publication Date	Title
MY151032A (en)	2014-03-31	Treatment of tnf? related disorders
EP0986382A4 (en)	2001-04-11	RAF KINASE HEMMER
MY121548A (en)	2006-02-28	Compounds and methods for the treatment of cancer
AU7321598A (en)	1998-09-22	Use of cholinesterase inhibitors to treat disorders of attention
ATE208210T1 (de)	2001-11-15	Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
AP9901478A0 (en)	1999-03-31	Compounds for the treatment of ischemia.
ATE372341T1 (de)	2007-09-15	Inhibitoren von mitotischem kinesin
TR200003206T2 (tr)	2001-07-23	İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
NO20003600D0 (no)	2000-07-13	Kaliumkanal inhibitorer
NO20003848D0 (no)	2000-07-27	FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
TR200000755T2 (tr)	2000-09-21	Karşıt olma-karşı gelme bozukluğunun tedavisi.
TR200401316T4 (tr)	2004-07-21	Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
AU2001260880A1 (en)	2001-11-20	Pharmaceutical compounds for treating copd
AU2576901A (en)	2001-06-25	Agents and methods for the treatment of proliferative diseases
TR199701613T1 (xx)	1998-04-21	Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
AU2013204147B2 (en)	2015-09-03	Treatment of TNFalpha related disorders
UA35854A (uk)	2001-04-16	Спосіб лікування приховано протікаючого силікотуберкульозу
UA32288A (uk)	2000-12-15	Спосіб лікування дегенеративних і запальних процесів
UA32108A (uk)	2000-12-15	Спосіб лікування хронічного тонзиліту
UA33359A (uk)	2001-02-15	Спосіб доступу до пухлин орбіти

Legal Events

Date	Code	Title	Description
2015-08-24	MM1K	Lapsed by not paying the annual fees